Choriocarcinoma of ovary

Summary

Choriocarcinoma of ovary (MONDO:0003507) is a disease and 5 clinical trials. Top therapeutic interventions include bleomycin sulfate and cisplatin. A subtype of choriocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	choriocarcinoma of ovary
Mondo ID	MONDO:0003507
EFO	EFO:1000413
DOID	DOID:5550
NCIT	C4515
SNOMED CT	254870004
UMLS	C0346181
MedGen	91089
GARD	0023536
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: choriocarcinoma of ovary · choriocarcinoma of the ovary · germ cell choriocarcinoma of ovary · germ cell choriocarcinoma of the ovary · ovarian choriocarcinoma · ovarian germ cell choriocarcinoma · ovary choriocarcinoma (disease)

Disease family

This is a subtype of choriocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › trophoblastic neoplasm › choriocarcinoma › choriocarcinoma of ovary

Related subtypes (7): pulmonary artery choriocarcinoma, choriocarcinoma of testis, gastric choriocarcinoma, non-gestational choriocarcinoma, choriocarcinoma of the central nervous system, gestational choriocarcinoma, placental site trophoblastic tumor

Subtypes (2): gestational ovarian choriocarcinoma, non-gestational ovarian choriocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03067181	PHASE3	RECRUITING	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT00467051	PHASE2	COMPLETED	Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
NCT00060372	PHASE1	COMPLETED	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01434355	Not specified	COMPLETED	DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN SULFATE	4	1
CISPLATIN	4	1